The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50 ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of GSK's respiratory ...
(RTTNews) - GSK plc (GSK, GSK.L) announced Monday that the US Food and Drug Administration has approved Arexvy, Respiratory Syncytial Virus or RSVVaccine, Adjuvanted, to prevent RSV lower ...
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in ...